Erste Group Plans Tender Offer to Boost Poland Bank Stake 
Apple Extends Qualcomm Patent Licensing Deal 
FDA Weighs Safety Standards for Psychedelic Therapies 
Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes 
OpenAI Agent Breaches Australia Medicare Data Portal 
Trump Signs Order to Cut Routine Childhood Vaccines 
Fed’s Hammack Says Bond Yield Surge Is Not Driven by Inflation Fears 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Gold Prices Fall as Treasury Yields Rise on Fed Rate Hike Bets 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
Dollar Holds Near Two-Month High as Yen Approaches 160 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
Add as a preferred source on Google
The Japanese Ministry of Health, Labor and Welfare has granted priority review status to the Alzheimer’s disease drug, lecanemab, of Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc.
Once the priority status has been granted, the target total review period is shortened.
Lecanemab was recently granted accelerated approval in the US.
A late-stage study showed the drug reduced the rate of cognitive decline in patients with early Alzheimer’s by 27 percent, compared with a placebo.
Similar experimental medications have largely all failed in the past.
Eisai also requested complete U.S. approval of the medication earlier this month. Food and Drug Administration (FDA) as a treatment for patients with neurodegenerative disease in its early stages.
